Canada Markets closed

Entheon Biomedical Corp. (ENTBF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.0502-0.0154 (-23.48%)
At close: 11:36AM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close0.0656
Open0.0638
BidN/A x N/A
AskN/A x N/A
Day's Range0.0502 - 0.0638
52 Week Range0.0490 - 0.5710
Volume3,435
Avg. Volume27,745
Market Cap3.103M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.1690
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Newsfile

    Entheon Biomedical Announces Non-Brokered Private Placement Financing

    Vancouver, British Columbia--(Newsfile Corp. - April 5, 2022) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biomedical company focused on the research and development of psychedelic drugs and leading-edge biomarkers to provide personalized treatment of addiction disorders, announces that it is proceeding on a non-brokered private placement financing of up to 30,000,000 Units (the "Units") at a price of CDN$0.10 per Unit for gross proceeds of up

  • Newsfile

    Entheon Biomedical Announces Expanded Psychedelics Genetic Test Panel & New Clinical Research Platform

    Improved Genetic Screening Platform to Strengthen Entheon's Psychedelic-Assisted Protocols Vancouver, British Columbia--(Newsfile Corp. - March 29, 2022) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biomedical company focused on the research and development of psychedelic drugs and leading-edge biomarkers to provide personalized treatment of addiction disorders, is pleased to announce that its expanded psychedelics genetic testing panel, devel

  • Newsfile

    Entheon Biomedical Announces Enrollment in Phase 1 Study of DMT

    Vancouver, British Columbia--(Newsfile Corp. - March 15, 2022) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biomedical company focused on the research and development of psychedelic drugs and leading-edge biomarkers to provide personalized treatment of addiction disorders, today announced that the first patient has been enrolled in the EBRX-101 study, a comprehensive phase I clinical trial evaluating the pharmacokinetics, pharmacodynamics and